I think the synergies with other treatments is overrated but otherwise it's spot on. We know with PD-1/PD-L1 checkpoint inhibitors they would add little to leronlimab's effect on PD-L1. They mention PARP inhibitors which stop DNA repair but leronlimab already does that. Chemotherapy can induce cancer reoccurrence that is resistant to that chemotherapy.